Analysis of the clinical antibacterial and antituberculosis pipeline

The Lancet Infectious Diseases

Volumn 19, Issue 2, 2019, Pages e40-e50

  Theuretzbacher, Ursula ^a   Gottwalt, Simon ^b   Beyer, Peter ^c   Butler, Mark ^d   Czaplewski, Lloyd ^e   Lienhardt, Christian ^c,f   Moja, Lorenzo ^c   Paul, Mical ^g   Paulin, Sarah ^c   Rex, John H ^h   Silver, Lynn L ⁱ   Spigelman, Melvin ^j   Thwaites, Guy E ^k   Paccaud, Jean Pierre ^l   Harbarth, Stephan ^m,n  

^a Center For Anti Infective Agents Vienna   (Austria)

^b Biovision Foundation for Sustainable Development   (Switzerland)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e Chemical Biology Ventures Limited   (United Kingdom)

^f UNIVERSITÉ DE MONTPELLIER   (France)

^g Infectious Diseases Unit   (Israel)

^h F2G LTD   (United Kingdom)

ⁱ LL Silver Consulting LLC   (United States)

^j GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^k OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^l Drugs for Neglected Diseases Initiative   (Switzerland)

^m GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁿ UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TUBERCULOSTATIC AGENT; CARBAPENEM DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CARBAPENEM RESISTANCE; CLOSTRIDIUM DIFFICILE INFECTION; CROSS RESISTANCE; HUMAN; MYCOBACTERIUM TUBERCULOSIS; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; WORLD HEALTH ORGANIZATION; CLOSTRIDIOIDES DIFFICILE; CLOSTRIDIUM INFECTION; DRUG EFFECT; GRAM NEGATIVE BACTERIUM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CARBAPENEMS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 85060681133     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30513-9     Document Type: Review

References (49)

1. Theuretzbacher, U, Global antimicrobial resistance in Gram-negative pathogens and clinical need. Curr Opin Microbiol 39 (2017), 106–112.
2. Potter, RF, D'Souza, AW, Dantas, G, The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat 29 (2016), 30–46.
3. Bassetti, M, Poulakou, G, Ruppe, E, Bouza, E, Van Hal, SJ, Brink, A, Antimicrobial resistance in the next 30 years, humankind, bugs and drugs. Intensive Care Med 43 (2017), 1464–1475.
4. Tacconelli, E, Carrara, E, Savoldi, A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18 (2017), 318–327.
5. WHO. Antibacterial products in clinical development for priority pathogens. http://www.who.int/research-observatory/monitoring/processes/antibacterial_products/en/, Sept 2017. (Accessed 4 February 2018)
6. The Pew Charitable Trusts. Antibiotics currently in global clinical development. http://www.pewtrusts.org/~/media/assets/2017/12/antibiotics_currently_in_clinical_development_09_2017.pdf?la=en, 2017. (Accessed 4 February 2018)
7. Butler, MS, Blaskovich, MA, Cooper, MA, Antibiotics in the clinical pipeline at the end of 2015. J Antibiot 70 (2017), 3–24.
8. Czaplewski, L, Bax, R, Clokie, M, et al. Alternatives to antibiotics— a pipeline portfolio review. Lancet Infect Dis 16 (2016), 239–251.
9. WHO. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. http://apps.who.int/iris/bitstream/10665/258965/1/WHO-EMP-IAU-2017.11-eng.pdf, 2017. (Accessed 4 February 2018)
10. WHO. Handbook for Guideline Development. http://apps.who.int/iris/bitstream/10665/75146/1/9789241548441_eng.pdf, 2012. (Accessed 4 February 2018)
11. Theuretzbacher, U, Antibiotic innovation for future public health needs. Clin Microbiol Infect 23 (2017), 713–717.
12. Magiorakos, AP, Srinivasan, A, Carey, RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
13. Potron, A, Poirel, L, Nordmann, P, Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 45 (2015), 568–585.
14. Nowak, P, Paluchowska, P, Acinetobacter baumannii: biology and drug resistance—role of carbapenemases. Folia Histochem Cytobiol 54 (2016), 61–74.
15. Moradali, MF, Ghods, S, Rehm, BHA, Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence. Front Cell Infect Microbiol, 7, 2017, 39.
16. Coleman, K, Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr Opin Microbiol 14 (2011), 550–555.
17. Bush, K, Game Changers: New β-lactamase inhibitor combinations targeting antibiotic resistance in Gram-negative bacteria. ACS Infect Dis 9 (2018), 84–87.
18. Livermore, DM, Mushtaq, S, Warner, M, Vickers, A, Woodford, N, In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrobl Chemother 72 (2017), 1373–1385.
19. Monogue, ML, Giovagnoli, S, Bissantz, C, Zampaloni, C, Nicolau, DP, In vivo efficacy of meropenem, with a novel non-β-lactam β-lactamase inhibitor, nacubactam, against Gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model. Antimicrob Agents Chemother, 2018 published online July 16. DOI:10.1128/AAC.02596-17.
20. Schalk, IJ, Mislin, GLA, Bacterial iron uptake pathways: gates for the import of bactericide compounds. J Med Chem 60 (2017), 4573–4576.
21. Hackel, MA, Tsuji, M, Yamano, Y, Echols, R, Karlowsky, JA, Sahm, DF, In vitro activity of the siderophore cephalosporin, cefiderocol, against carbapenem-nonsusceptible and multidrug-resistant isolates of gram-negative bacilli collected worldwide in 2014 to 2016. Antimicrob Agents Chemother 62 (2018), e01968–e002017.
22. Grossman, TH, Tetracycline antibiotics and resistance. Cold Spring Harb Perspect Med, 6, 2016, a025387.
23. Sader, HS, Mendes, RE, Pfaller, MA, Shortridge, D, Flamm, RK, Castanheira, M, Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 62 (2018), e01856–e01917.
24. Palzkill, T, Metallo-β-lactamase structure and function. Ann N Y Acad Sci 1277 (2013), 91–104.
25. Livermore, DM, Mushtaq, S, Warner, M, Turner, SJ, Woodford, N, Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother 73 (2018), 126–133.
26. Peyclit, L, Baron, SA, Yousfi, H, Rolain, JM, Zidovudine: a salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections?. Int J Antimicrob Agents 52 (2018), 11–13.
27. Andolina, G, Bencze, L-C, Zerbe, K, et al. A peptidomimetic antibiotic interacts with the periplasmic domain of LptD from Pseudomonas aeruginosa. ACS Chem Biol 13 (2018), 666–675.
28. Sader, HS, Flamm, RK, Dale, GE, Rhomberg, PR, Castanheira, M, Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. J Antimicrob Chemother, 2018 published online June 12. DOI:10.1093/jac/dky227.
29. McLeod S, Carter N, Hackel M, et al. The novel β-lactamase Inhibitor ETX1317 effectively restores the activity of cefpodoxime against extended spectrum β-lactamase (ESBL) and carbapenemase-expressing Enterobacteriaceae isolated from recent urinary tract infection. ASM Microbe 2018, Atlanta, USA, P603.
30. Alban, L, Ellis-Iversen, J, Andreasen, M, Dahl, J, Sönksen, UW, Assessment of the risk to public health due to use of antimicrobials in pigs—an example of pleuromutilins in Denmark. Front Vet Sci, 4, 2017, 74.
31. van Eijk, E, Wittekoek, B, Kuijper, EJ, Smits, WK, DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens. J Antimicrob Chemother 72 (2017), 1275–1284.
32. Jacobsson, S, Golparian, D, Scangarella-Oman, N, Unemo, M, In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother 73 (2018), 2072–2077.
33. Alm, RA, Lahiri, SD, Kutschke, A, et al. Characterization of the novel dna gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 59 (2015), 1478–1486.
34. Chikhale, RV, Barmade, MA, Murumkar, PR, Yadav, MR, Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis. J Med Chem, 2018 published online June 12. DOI:10.1021/acs.jmedchem.8b00281.
35. Silver, LL, Challenges of antibacterial discovery. Clin Microbiol Rev 24 (2011), 71–109.
36. Karlowsky, JA, Lob, SH, Kazmierczak, KM, et al. In vitro activity of imipenem against carbapenemase-positive Enterobacteriaceae isolates collected by the smart global surveillance program from 2008 to 2014. J Clin Microbiol 55 (2017), 1638–1649.
37. Deshpande, LM, Mendes, RE, Smith, CJ, Castanheira, M, Global trends in prevalence and diversity of carbapenemases carrying Enterobacteriaceae identified through SENTRY antimicrobial surveillance program. ASM Microbe, Atlanta, USA, P404. https://www.jmilabs.com/data/posters/ASM-Microbe-2018-SENTRY-carbapenemases.pdf. (Accessed 21 August 2018)
38. Hackel M, Sahm D. Antimicrobial activity of cefepime in combination with VNRX-5133 against a global collection of clinical isolates. 28th European Congress of Clinical Microbiology & Infectious Disease, Madrid, Spain, 2018, P1543.
39. Falagas, ME, Skalidis, T, Vardakas, KZ, Legakis, NJ, Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals. J Antimicrob Chemother 72 (2017), 1704–1708.
40. Bebbington, C, Yarranton, G, Antibodies for the treatment of bacterial infections: current experience and future prospects. Curr Opin Biotechnol 19 (2008), 613–619.
41. François, B, Barraud, O, Jafri, HS, Antibody-based therapy to combat Staphylococcus aureus infections. Clin Microbiol Inf 23 (2017), 219–221.
42. Saylor, C, Dadachova, E, Casadevall, A, Monoclonal antibody-based therapies for microbial diseases. Vaccine 27:suppl 6 (2009), G38–G46.
43. Bassères, E, Endres, BM, Dotson, K, Alam, PMJ, Garey, K, Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol 33 (2017), 1–7.
44. Khanafer, N, Daneman, N, Greene, T, et al. Susceptibilities of clinical Clostridium difficile isolates to antimicrobials: a systematic review and meta-analysis of studies since 1970. Clin Microb Inf 24 (2018), 110–117.
45. Falzon, D, Schünemann, HJ, Harausz, E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J, 49, 2017, 1602308.
46. Lange, C, Alghamdi, WA, Al-Shaer, MH, et al. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. J Intern Med 284 (2018), 163–188.
47. Lienhardt, C, Lönnroth, K, Menzies, D, et al. Translational research for tuberculosis elimination: priorities, challenges, and actions. PLoS Med, 13, 2016, e1001965.
48. Tiberi, S, du Plessis, N, Walzl, G, et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis 18 (2018), e183–e198.
49. Singh, V, Mizrahi, V, Identification and validation of novel drug targets in Mycobacterium tuberculosis. Drug Discov Today 22 (2017), 503–509.